Karen L Lindsay

Summary

Affiliation: University of Southern California
Country: USA

Publications

  1. pmc Comparison of amplification enzymes for Hepatitis C Virus quasispecies analysis
    Stephen J Polyak
    Virology Division, Department of Laboratory Medicine, University of Washington, Seattle, WA, USA
    Virol J 2:41. 2005
  2. ncbi request reprint Introduction to therapy of hepatitis C
    Karen L Lindsay
    Keck School of Medicine, University of Southern California, Los Angeles 90033, CA, USA
    Hepatology 36:S114-20. 2002
  3. doi request reprint Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C
    Karen L Lindsay
    Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA
    Clin Gastroenterol Hepatol 6:234-41. 2008
  4. pmc Outcome of sustained virological responders with histologically advanced chronic hepatitis C
    Timothy R Morgan
    Division of Gastroenterology, University of California Irvine, Irvine, CA, USA
    Hepatology 52:833-44. 2010
  5. ncbi request reprint Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy
    Kung Chia Young
    Department of Molecular Microbiology and Immunology, University of Southern California, Keck School of Medicine, 2011 Zonal Avenue, Los Angeles, CA 90089 9094, USA
    Hepatology 38:869-78. 2003
  6. pmc Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes
    Keigo Machida
    Department of Molecular Microbiology and Immunology, University of Southern California Keck School of Medicine, 2011 Zonal Avenue, Los Angeles, CA 90033, USA
    Proc Natl Acad Sci U S A 101:4262-7. 2004
  7. ncbi request reprint More advanced hepatic fibrosis in hispanics with chronic hepatitis C infection: role of patient demographics, hepatic necroinflammation, and steatosis
    Sumita Verma
    Division of Gastrointestinal and Liver Diseases, Hepatitis Research and Treatment Center, Los Angeles, California, USA
    Am J Gastroenterol 101:1817-23. 2006
  8. pmc Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection
    Vicky M H Sung
    Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA
    J Virol 77:2134-46. 2003
  9. pmc Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C
    Chihiro Morishima
    Department of Laboratory Medicine, Virology Division, University of Washington, Seattle, WA, USA
    Hepatology 48:1412-9. 2008
  10. pmc Inadequate numbers
    Karen L Lindsay
    Can Fam Physician 53:401; author reply 401-2. 2007

Collaborators

Detail Information

Publications27

  1. pmc Comparison of amplification enzymes for Hepatitis C Virus quasispecies analysis
    Stephen J Polyak
    Virology Division, Department of Laboratory Medicine, University of Washington, Seattle, WA, USA
    Virol J 2:41. 2005
    ..QS diversity and complexity were quantified using heteroduplex mobility assays (HMA)...
  2. ncbi request reprint Introduction to therapy of hepatitis C
    Karen L Lindsay
    Keck School of Medicine, University of Southern California, Los Angeles 90033, CA, USA
    Hepatology 36:S114-20. 2002
    ....
  3. doi request reprint Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C
    Karen L Lindsay
    Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA
    Clin Gastroenterol Hepatol 6:234-41. 2008
    ..Although viral kinetic profiles in treatment responders shed light on the mechanism of action of interferon and ribavirin, minimal information is available to explain why some patients experience little or no virologic suppression...
  4. pmc Outcome of sustained virological responders with histologically advanced chronic hepatitis C
    Timothy R Morgan
    Division of Gastroenterology, University of California Irvine, Irvine, CA, USA
    Hepatology 52:833-44. 2010
    ..CONCLUSION: Patients with advanced chronic hepatitis C who achieved SVR had a marked reduction in death/liver transplantation, and in liver-related morbidity/mortality, although they remain at risk for HCC...
  5. ncbi request reprint Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy
    Kung Chia Young
    Department of Molecular Microbiology and Immunology, University of Southern California, Keck School of Medicine, 2011 Zonal Avenue, Los Angeles, CA 90089 9094, USA
    Hepatology 38:869-78. 2003
    ..Furthermore, the selection of an RBV-resistant variant with a single amino acid substitution in NS5B suggested that RBV may directly interact with HCV RNA polymerase, thus interfering with its enzymatic activity...
  6. pmc Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes
    Keigo Machida
    Department of Molecular Microbiology and Immunology, University of Southern California Keck School of Medicine, 2011 Zonal Avenue, Los Angeles, CA 90033, USA
    Proc Natl Acad Sci U S A 101:4262-7. 2004
    ..These results indicate that HCV induces a mutator phenotype and may transform cells by a hit-and-run mechanism. This finding provides a mechanism of oncogenesis for an RNA virus...
  7. ncbi request reprint More advanced hepatic fibrosis in hispanics with chronic hepatitis C infection: role of patient demographics, hepatic necroinflammation, and steatosis
    Sumita Verma
    Division of Gastrointestinal and Liver Diseases, Hepatitis Research and Treatment Center, Los Angeles, California, USA
    Am J Gastroenterol 101:1817-23. 2006
    ..We sought to assess whether Hispanics have more advanced hepatitis C virus (HCV)-related liver disease than non-Hispanic whites (NHW) and to identify contributory factors...
  8. pmc Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection
    Vicky M H Sung
    Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA
    J Virol 77:2134-46. 2003
    ..HCV-infected cell lines show significantly enhanced apoptosis. These B-cell lines provide a reproducible cell culture system for studying the complete replication cycle and biology of HCV infections...
  9. pmc Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C
    Chihiro Morishima
    Department of Laboratory Medicine, Virology Division, University of Washington, Seattle, WA, USA
    Hepatology 48:1412-9. 2008
    ..With continued treatment, patients with inconsistently positive TMA results were more likely to become TMA-negative than TMA-positive (P < 0.0001)...
  10. pmc Inadequate numbers
    Karen L Lindsay
    Can Fam Physician 53:401; author reply 401-2. 2007
  11. ncbi request reprint Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C
    Robert J Fontana
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109 0362, USA
    Hepatology 45:1154-63. 2007
    ....
  12. ncbi request reprint Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial
    Anna S F Lok
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan 48109 0362, USA
    Clin Gastroenterol Hepatol 5:245-54. 2007
    ....
  13. ncbi request reprint Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA 23298, USA
    Gastroenterology 132:103-12. 2007
    ..However, prior studies did not assess the impact of reducing the dose of peginterferon independent of ribavirin or differentiate between dose reduction or interrupting or prematurely discontinuing treatment...
  14. ncbi request reprint HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial
    Chihiro Morishima
    Department of Laboratory Medicine, University of Washington, Seattle, WA 98104, USA
    Hepatology 44:360-7. 2006
    ..In patients with negative PCR results during treatment, a single positive TMA test did not exclude SVR, although persistently positive tests did...
  15. ncbi request reprint Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial
    Leonard B Seeff
    Division of Digestive Diseases and Nutrition, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Hepatology 47:605-12. 2008
    ..Because its use among these HALT-C participants was self-motivated and uncontrolled, however, only a well-designed prospective study can determine whether silymarin provides benefit to persons with chronic hepatitis C...
  16. ncbi request reprint Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C
    Chihiro Morishima
    Department of Laboratory Medicine and Pediatrics, University of Washington, Seattle, USA
    J Infect Dis 193:931-40. 2006
    ..Thus, in patients with advanced hepatic fibrosis due to HCV infection, pretreatment HCV-specific immune responses and increased QS variability appear to hinder viral clearance by pegylated IFN- alpha 2a and ribavirin combination therapy...
  17. ncbi request reprint Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C
    John G McHutchison
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715, USA
    Gastroenterology 123:1061-9. 2002
    ..We evaluated the impact of adherence to combination therapy with interferon or peginterferon plus ribavirin in chronic hepatitis C patients...
  18. ncbi request reprint Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University, Richmond, 23298, USA
    Gastroenterology 126:1015-23; discussion 947. 2004
    ..This study evaluated the effectiveness of this treatment in patients who were nonresponders to previous interferon-based therapy...
  19. ncbi request reprint Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders
    William M Lee
    Control Clin Trials 25:472-92. 2004
    ..The protocol changes enhanced enrollment while upholding the original goals of the study and its integrity...
  20. ncbi request reprint Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C
    Alan Lee Rothman
    Center for Infectious Disease and Vaccine Research and Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA
    Hepatology 41:617-25. 2005
    ....
  21. ncbi request reprint Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort
    Anna S F Lok
    Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Ann Arbor, MI 48210, USA
    Hepatology 42:282-92. 2005
    ..In conclusion, a model based on standard laboratory test results can be used to predict histological cirrhosis with a high degree of accuracy in 50% of patients with CHC...
  22. ncbi request reprint Cognitive reserve and neuropsychological functioning in patients infected with hepatitis C
    Linas A Bieliauskas
    Neuropsychology Section, Department of Psychiatry, University of Michigan Medical Center, Ann Arbor, Michigan 48105, USA
    J Int Neuropsychol Soc 13:687-92. 2007
    ..It is important to account for CRS when assessing cognitive findings in large-scale clinical trials...
  23. ncbi request reprint Treatment of chronic hepatitis C infection: one step at a time
    Gary L Davis
    Division of Hepatology, Baylor University Medical Center and Baylor Regional Transplant Institute, Dallas, Texas 75246, USA
    Lancet Infect Dis 5:524-6. 2005
    ..Drugs that directly act on the replicative machinery of the virus-protease and polymerase inhibitors-are under development and entering clinical trials in human beings...
  24. ncbi request reprint Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial
    Adrian M Di Bisceglie
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Saint Louis University School of Medicine, 3635 Vista Avenue, St Louis, MO 63110, USA
    J Hepatol 43:434-41. 2005
    ..We assessed serum AFP among patients with chronic hepatitis C and advanced fibrosis to establish predictors of AFP elevations and changes with antiviral therapy...
  25. ncbi request reprint Cognitive function in hepatitis C patients with advanced fibrosis enrolled in the HALT-C trial
    Robert J Fontana
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI 48109 0362, USA
    J Hepatol 43:614-22. 2005
    ..The aim of this study was to determine the frequency, type, and severity of cognitive impairment in a large group of CHC patients with advanced fibrosis...
  26. ncbi request reprint Clinical relevance of cognitive scores in hepatitis C patients with advanced fibrosis
    Linas A Bieliauskas
    University of Michigan Medical Center, Ann Arbor, MI, USA
    J Clin Exp Neuropsychol 28:1346-61. 2006
    ..There was a significant correlation between cognitive impairment and self-reported depression...
  27. ncbi request reprint Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis
    Burton Combes
    The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390 9151, USA
    Hepatology 42:1184-93. 2005
    ..In conclusion, methotrexate when added to UDCA for a median period of 7.6 years had no effect on the course of PBC treated with UDCA alone...